A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants
Status:
Completed
Trial end date:
2022-08-23
Target enrollment:
Participant gender:
Summary
This sub-study will assess the pharmacokinetics (PK), safety, tolerability, virologic
efficacy and health outcomes of CAB (GSK1265744) and RPV long acting (LA) in HIV-infected
adult participants currently enrolled in the Antiretroviral Therapy as Long Acting
Suppression every 2 Months (ATLAS2M [A2M]) study (NCT03299049).